CLEVELAND, OH, United States
CLEVELAND, OH, United States
SEARCH FILTERS
Time filter
Source Type

Regenerative Medicine Market is estimated at $20.07 billion in 2015 and is projected to reach $101.3 billion by 2022 growing at a CAGR of 26.0% from 2015 to 2022Pune , India - April 24, 2017 /MarketersMedia/ — Regenerative Medicine Industry Description According to Stratistics MRC, the Regenerative Medicine Market is estimated at $20.07 billion in 2015 and is projected to reach $101.3 billion by 2022 growing at a CAGR of 26.0% from 2015 to 2022. Growing research applications, growing demand in tissue engineering, biomaterials and stem cell therapy systems are some of the factors driving the market growth. However, high cost associated with biomaterials will be a major factor to restrict the market growth. The stem cells application and advancements in nanotechnology will further drive the market over the forecast period. Gene therapies segment is expected to be the fastest emerging technology due to tremendous potential of gene therapy in minimizing immune rejections, which commonly occur after transplantations. Asia-Pacific would be the fastest growing region for regenerative medicine market. Europe and North America together accounted for over 3/4th of the market revenue and anticipated to be most profitable regional market. Some of the key players in the market include Shire Pharmaceuticals, Advanced Cell Technology, Inc, Genzyme, Athersys, Inc., Kinetic Concepts, Inc., NuVasive Inc., Stem cells, Inc., Cytori Therapeutics, Inc., Cytomedix Inc., Mesoblast Ltd. , Zimmer Holdings, Inc., Orthofix, DePuy Synthes Inc., Cell Medica and CryoLife. Request for Sample Report @ https://www.wiseguyreports.com/sample-request/456590-regenerative-medicine-global-market-outlook-2015-2022 Technologies Covered: • Small Molecules and Biologics • Gene Therapy • Cell Therapy Applications Covered: • Dermatology • Cardiovascular Disorders • Central Nervous System (CNS) • Orthopedic • Dental • Other applications o Autoimmune Diseases o Muscle Regeneration o Ocular Diseases o Internal organ regeneration Leave a Query @ https://www.wiseguyreports.com/enquiry/456590-regenerative-medicine-global-market-outlook-2015-2022 Regions Covered: • North America o US o Canada o Mexico • Europe o Germany o France o Italy o UK o Spain o Rest of Europe • Asia Pacific o Japan o China o India o Australia o New Zealand o Rest of Asia Pacific • Rest of the World o Middle East o Brazil o Argentina o South Africa o Egypt What our report offers: - Market share assessments for the regional and country level segments - Market share analysis of the top industry players - Strategic recommendations for the new entrants - Market forecasts for a minimum of 7 years of all the mentioned segments, sub segments and the regional markets - Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations) - Strategic recommendations in key business segments based on the market estimations - Competitive landscaping mapping the key common trends - Company profiling with detailed strategies, financials, and recent developments - Supply chain trends mapping the latest technological advancements Buy now @ https://www.wiseguyreports.com/checkout?currency=one_user-USD&report_id=456590 Continued... Contact Us: Sales@Wiseguyreports.Com Ph: +1-646-845-9349 (US) Ph: +44 208 133 9349 (UK) Contact Info:Name: NORAH TRENTEmail: sales@wiseguyreports.comOrganization: WISE GUY RESEARCH CONSULTANTS PVT LTDAddress: Office No. 528, Amanora Chambers Magarpatta Road, Hadapsar Pune - 411028Phone: +91 841 198 5042Source URL: http://marketersmedia.com/regenerative-medicine-market-2017-global-share-trend-and-opportunities-forecast-to-2022/189453For more information, please visit https://www.wiseguyreports.com/sample-request/456590-regenerative-medicine-global-market-outlook-2015-2022Source: MarketersMediaRelease ID: 189453


Browse 350 Tables and Figures, 17 Companies spread across 680 pages, available at http://www.reportsnreports.com/reports/974420-global-regenerative-medicine-market-analysis-forecast-to-2021-stem-cells-tissue-engineering-biobanking-car-t-industries.html . Analysis indicates that the global regenerative medicine market was worth $18.9 billion in 2016 and will grow to over $53.7 billion by 2021, with a CAGR of 23.3% between this time frame. Within this market, the stem cell industry will grow significantly at a CAGR of over x% and reach $x billion by 2021. Tissue engineering is forecast to grow at a CAGR of x% to 2021 and potentially reach $x billion. Companies Mentioned are Astellas Institute for Regenerative Medicine (Ocata Therapeutics), AstraZeneca, Athersys, Baxter International (Baxalta,  Shire), Bayer, Caladrius Biosciences (NeoStem), Celgene, CHA Biotech, Chimerix, Cynata Therapeutics, Cytori Therapeutics, Eisai, Genzyme (Sanofi), GSK, Janssen, InCyte Corp, MedImmune, MEDIPOST, Merck, Mesoblast, Millennium Pharmaceutical, NuVasive, Osiris Therapeutics, Plasticell, Pluristem Therapeutics, Pfizer, SanBio Current Stem Cell Trials, Seattle Genetics Current Stem Cell Trials, StemCells Inc, STEMCELL Technologies, Takara Bio, Teva Current Stem Cell Trials and Tigenix This report describes the evolution of such a huge market in 15 chapters, which provides an overview of regenerative medicine that includes: stem cells, allogenic and autogenic cells, umbilical cord blood banking, tissue engineering and CAR T therapies. Global regenerative medicine market, global breakdown, application breakdown and leading market players. Detailed account of the stem cell industry market by geography, indication and company profiles. Profiles, marketed/pipeline products, financial analysis and business strategy of the major companies in this space. Focus on current trends, business environment, pipeline products, clinical trials, and future market forecast for regenerative medicine. Insight into the challenges faced by stakeholders, particularly about the success vs. failure ratios in developing regenerative medicine drugs and therapies. Insight into the biobanking industry globally and its impact on the overall market. Description and data for the prevalence of disease types that are addressed by regenerative medicine, stem cells, tissue engineering and CAR-T therapies. Financial market forecast through 2021 with CAGR values of all market segments outlined in the objective. SWOT analysis of the global market. Geographical analysis and challenges within key topographies including the USA, Japan, South Korea, China and Europe Looking forward, the regenerative medicine market is promising for a number of robust reasons including: There are over 700 regenerative medicine companies globally at present, that all together have a $x billion market cap. At present the total regenerative medicine market has more than 500 products commercialized.  The regenerative medicine market encompasses a number of key technology submarkets including: Cell therapy including stem cells, Tissue Engineering, Biomaterials and BioBanking Regenerative medicine, including cellular and gene therapies will have a significant impact on the expenditure of payers, once reimbursement schemes are optimized. To that end a number of conditions that regenerative medicine tackles is synonymous with an aging population such as The report further provides: Global Regenerative Market by Manufacturers, Regions, Type and Application, Forecast to 2021 Personalized Medicine, Targeted Therapeutics and Companion Diagnostic Market to 2021- Strategic Analysis of Industry Trends, Technologies, Participants, and Environment Large Cap Pharma US & EU Outlook 2016: Maximizing Their Strength On Fewer Therapy Class, Personalized Medicine, Novel Target And Biosimilars For Future Growth Explore more reports on Biotechnology Market at http://www.reportsnreports.com/market-research/biotechnology/. ReportsnReports.com is an online market research reports library of 500,000+ in-depth studies of over 5000 micro markets. Not limited to any one industry, ReportsnReports.com offers research studies on agriculture, energy and power, chemicals, environment, medical devices, healthcare, food and beverages, water, advanced materials and much more.


Browse 350 Tables and Figures, 17 Companies spread across 680 pages, available at http://www.reportsnreports.com/reports/974420-global-regenerative-medicine-market-analysis-forecast-to-2021-stem-cells-tissue-engineering-biobanking-car-t-industries.html . Analysis indicates that the global regenerative medicine market was worth $18.9 billion in 2016 and will grow to over $53.7 billion by 2021, with a CAGR of 23.3% between this time frame. Within this market, the stem cell industry will grow significantly at a CAGR of over x% and reach $x billion by 2021. Tissue engineering is forecast to grow at a CAGR of x% to 2021 and potentially reach $x billion. Companies Mentioned are Astellas Institute for Regenerative Medicine (Ocata Therapeutics), AstraZeneca, Athersys, Baxter International (Baxalta,  Shire), Bayer, Caladrius Biosciences (NeoStem), Celgene, CHA Biotech, Chimerix, Cynata Therapeutics, Cytori Therapeutics, Eisai, Genzyme (Sanofi), GSK, Janssen, InCyte Corp, MedImmune, MEDIPOST, Merck, Mesoblast, Millennium Pharmaceutical, NuVasive, Osiris Therapeutics, Plasticell, Pluristem Therapeutics, Pfizer, SanBio Current Stem Cell Trials, Seattle Genetics Current Stem Cell Trials, StemCells Inc, STEMCELL Technologies, Takara Bio, Teva Current Stem Cell Trials and Tigenix This report describes the evolution of such a huge market in 15 chapters, which provides an overview of regenerative medicine that includes: stem cells, allogenic and autogenic cells, umbilical cord blood banking, tissue engineering and CAR T therapies. Global regenerative medicine market, global breakdown, application breakdown and leading market players. Detailed account of the stem cell industry market by geography, indication and company profiles. Profiles, marketed/pipeline products, financial analysis and business strategy of the major companies in this space. Focus on current trends, business environment, pipeline products, clinical trials, and future market forecast for regenerative medicine. Insight into the challenges faced by stakeholders, particularly about the success vs. failure ratios in developing regenerative medicine drugs and therapies. Insight into the biobanking industry globally and its impact on the overall market. Description and data for the prevalence of disease types that are addressed by regenerative medicine, stem cells, tissue engineering and CAR-T therapies. Financial market forecast through 2021 with CAGR values of all market segments outlined in the objective. SWOT analysis of the global market. Geographical analysis and challenges within key topographies including the USA, Japan, South Korea, China and Europe Looking forward, the regenerative medicine market is promising for a number of robust reasons including: There are over 700 regenerative medicine companies globally at present, that all together have a $x billion market cap. At present the total regenerative medicine market has more than 500 products commercialized.  The regenerative medicine market encompasses a number of key technology submarkets including: Cell therapy including stem cells, Tissue Engineering, Biomaterials and BioBanking Regenerative medicine, including cellular and gene therapies will have a significant impact on the expenditure of payers, once reimbursement schemes are optimized. To that end a number of conditions that regenerative medicine tackles is synonymous with an aging population such as The report further provides: Global Regenerative Market by Manufacturers, Regions, Type and Application, Forecast to 2021 Personalized Medicine, Targeted Therapeutics and Companion Diagnostic Market to 2021- Strategic Analysis of Industry Trends, Technologies, Participants, and Environment Large Cap Pharma US & EU Outlook 2016: Maximizing Their Strength On Fewer Therapy Class, Personalized Medicine, Novel Target And Biosimilars For Future Growth Explore more reports on Biotechnology Market at http://www.reportsnreports.com/market-research/biotechnology/. ReportsnReports.com is an online market research reports library of 500,000+ in-depth studies of over 5000 micro markets. Not limited to any one industry, ReportsnReports.com offers research studies on agriculture, energy and power, chemicals, environment, medical devices, healthcare, food and beverages, water, advanced materials and much more.


On Thursday, shares in Lexington, Massachusetts headquartered Agenus Inc. recorded a trading volume of 605,692 shares. The stock ended the session 1.69% higher at $3.61. The Company's shares have gained 6.49% in the last one month. The stock is trading 3.04% below its 50-day moving average. Moreover, shares of Agenus, which focuses on the discovery and development of therapies that engage the body's immune system for patients suffering with cancer, have a Relative Strength Index (RSI) of 47.55. On May 04th, 2017, Agenus provided a corporate update and reported financial results for Q1 ended March 31st, 2017. The Company reported revenue of $26.96 million for Q1 2017; R&D expense of $32.64 million; general and administrative expense of $7.77 million; and net loss of $17.1 million. In addition, cash, cash equivalents and short-term investments were $124 million as of March 31st, 2017. The free research report on AGEN is available at: Cleveland, Ohio headquartered Athersys Inc.'s stock closed the day 1.37% lower at $1.44 with a total trading volume of 533,664 shares. The Company's shares have advanced 22.03% in the previous three months. The stock is trading 2.68% above its 50-day moving average. Additionally, shares of Athersys, which focuses on the research and development activities in the field of regenerative medicine, have an RSI of 51.21. On May 09th, 2017, Athersys announced its financial results for the three months ended March 31st, 2017. Revenues were $1.5 million for Q1 2017; R&D expenses decreased to $5.6 million; and net loss was $5.6 million. Cash used in operating activities was $5.4 million during Q1 2017, and cash and cash equivalents balance was $31.9 million. The complimentary report on ATHX can be downloaded at: Shares in New York-based Actinium Pharmaceuticals Inc. recorded a trading volume of 155,920 shares. The stock ended yesterday's trading session 0.76% higher at $1.32. The Company's shares have advanced 50.86% on an YTD basis. The stock is trading below its 200-day moving average by 0.30%. Furthermore, shares of Actinium Pharma, which develops targeted payload immunotherapeutics for the treatment of advanced cancers, have an RSI of 37.08. On May 17th, 2017, Actinium Pharma announced that Dr. Richard Stone, Chief of Staff and Program Director, Acute Leukemia at the Dana-Farber Cancer Institute and Professor of Medicine at Harvard Medical School, has joined the Company's Scientific Advisory Board (SAB). SAB is comprised of independent physicians considered to be key opinion leaders in the field of hematology and bone marrow transplant that contribute to and advise Actinium on the development of Iomab-B, the Company's lead asset. Visit us today and download our complete research report on ATNM for free at: Cambridge, Massachusetts-based AVEO Pharmaceuticals Inc.'s stock finished Thursday's session 9.68% higher at $0.68 with a total trading volume of 383,245 shares. The Company's shares have advanced 17.24% in the last one month and 25.93% since the start of this year. The stock is trading above its 50-day moving average by 2.62%. Additionally, shares of AVEO Pharma, which develops targeted therapies for cancer and related diseases, have an RSI of 59.13. On May 16th, 2017, AVEO Oncology, also AVEO Pharmaceuticals, announced the appointment of Matthew Dallas as chief financial officer, effective June 01st, 2017. In this role, Mr. Dallas will be responsible for the Company's financial strategy and management as it takes steps toward the potential commercialization of tivozanib. Mr. Dallas will also serve on the executive leadership team, which governs corporate strategy at AVEO. Get free access to your technical report on AVEO at: Stock Callers (SC) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. SC has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below. SC has not been compensated; directly or indirectly; for producing or publishing this document. The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email info@stock-callers.com. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by SC. SC is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way. SC, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. SC, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, SC, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice. This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither SC nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit CONTACT For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at: Email: info@stock-callers.com Phone number:  +44-330-808-3765 Office Address: Clyde Offices, Second Floor, 48 West George Street, Glasgow, U.K. -G2 1BP CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

Loading Athersys, Inc. collaborators
Loading Athersys, Inc. collaborators